<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Morepen Laboratories Ltd. on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/morepen-laboratories-ltd./</link>
    <description>Recent content in Morepen Laboratories Ltd. on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 17 May 2025 18:25:24 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/morepen-laboratories-ltd./index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Morepen Laboratories Ltd - May 2025 Earnings Call Transcript Analysis</title>
      <link>https://reports.muthu.co/posts/morepen-laboratories-ltd---may-2025-earnings-call-transcript-analysis/</link>
      <pubDate>Sat, 17 May 2025 18:25:24 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/morepen-laboratories-ltd---may-2025-earnings-call-transcript-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;earnings-call-transcript-analysis-report&#34;&gt;&#xA;  Earnings Call Transcript Analysis Report&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#earnings-call-transcript-analysis-report&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;morepen-laboratories-q4-fy25-earnings-analysis&#34;&gt;&#xA;  Morepen Laboratories Q4 FY25 Earnings Analysis&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#morepen-laboratories-q4-fy25-earnings-analysis&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;financial-performance&#34;&gt;&#xA;  Financial Performance&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-performance&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;Morepen Laboratories reported mixed financial results for Q4 FY25 and the full year FY25.&lt;/p&gt;&#xA;&lt;h4 class=&#34;heading&#34; id=&#34;key-financial-metrics--comparison&#34;&gt;&#xA;  Key Financial Metrics &amp;amp; Comparison&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#key-financial-metrics--comparison&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h4&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Annual FY25 Revenue:&lt;/strong&gt; INR 1,830 crores, a 7.4% increase from INR 1,704 crores in FY24. Management noted this was &amp;ldquo;lower than expected,&amp;rdquo; aiming for 10-15%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;So last year, we had clocked a turnover of INR1,700 crores, INR1,704 crores. And this year, it is INR1,830 crores, 7.4% increase in the revenue, which is lower than expected.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Q4 FY25 Revenue:&lt;/strong&gt; INR 470 crores, a 10.1% increase from INR 427 crores in Q4 FY24.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;And in the year as a whole, for the quarter, it is 10.1% from INR427 crores last year, now this year, it is INR470 crores.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Annual FY25 EBITDA:&lt;/strong&gt; Increased by 11.5% year-over-year. EBITDA margin improved by 40 bps to 10.5% from 10.1%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;EBITDA has increased by 11% against 7% increase in revenue, 11.5% increase in EBITDA. EBITDA percentage from 10.1% to 10.5%, almost 0.4%, which is like, I would say, 40 bps has increased.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Annual FY25 PAT:&lt;/strong&gt; Increased by 22% year-over-year.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;PAT percentage has increased 22%.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Q4 FY25 EBITDA &amp;amp; PAT:&lt;/strong&gt; Declined year-over-year despite revenue growth, attributed to deferred export orders and non-repeat of large bulk orders from the previous year&amp;rsquo;s same quarter.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;The EBITDA had gone down&amp;hellip; because of the lower exports, our EBITDA has gone down in the last quarter. And EBITDA has gone down, I don&amp;rsquo;t have to tell that PAT would also go up (likely meant &amp;lsquo;go down&amp;rsquo;).&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Gross Margins:&lt;/strong&gt; Faced pressure, particularly in the API business due to price declines. A sharp sequential and YoY decline was noted, partly due to API price fall and partly due to accounting changes (AS 116) shifting some lease rental expenses from &amp;ldquo;Other Expenses&amp;rdquo; to &amp;ldquo;Depreciation.&amp;rdquo;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;CFO Quote: &amp;ldquo;Gross margin, we have already mentioned that there is a bit of price falling. It has affected our EBITDA margin in the API business.&amp;rdquo;&lt;/li&gt;&#xA;&lt;li&gt;CFO Quote on expense reclassification: &amp;ldquo;early rent was charged to expense. Now as per AS 116, so we had amortized it. So that part from other expenses that has gone to the depreciation.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h4 class=&#34;heading&#34; id=&#34;revised-guidance-or-forecasts&#34;&gt;&#xA;  Revised Guidance or Forecasts&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#revised-guidance-or-forecasts&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h4&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;No formal guidance, but management indicated they are &amp;ldquo;working between 10% to 15%&amp;rdquo; for company-level revenue growth for FY26 and FY27.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote: &amp;ldquo;We usually do not give any guidance, but we are working between 10% to 15%.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;Expectation for every quarter to &amp;ldquo;touch &amp;ndash; every quarter should be INR500 crores.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h4 class=&#34;heading&#34; id=&#34;areas-of-growth-or-decline&#34;&gt;&#xA;  Areas of Growth or Decline&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#areas-of-growth-or-decline&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h4&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Growth (Annual):&lt;/strong&gt; Overall revenue, EBITDA, PAT. Medical Devices segment revenue grew 12% YoY (INR 496 crores). Formulation revenue grew 21% over two years (INR 344 crores in FY25). API exports grew 26% in value over 3 years, reaching 72.1% of API sales. New API product contribution grew 65% in 3 years to INR 114 crores.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Decline (Q4):&lt;/strong&gt; Q4 EBITDA and PAT declined despite revenue growth. API business saw muted revenue growth (3.5% annually, 4% in Q4) primarily due to significant price drops (average selling price down 24% in 2 years), despite a 57% increase in sales quantity over two years.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote on API pricing: &amp;ldquo;From an average of INR26,000 per kg, we have come to INR20,000 per kg, INR20,300 per kg. So basically, this price drop is one thing which we had to absorb.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;strategic-initiatives--business-updates&#34;&gt;&#xA;  Strategic Initiatives &amp;amp; Business Updates&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#strategic-initiatives--business-updates&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;The company is focusing on expanding high-margin businesses, increasing export contribution, and new product development.&lt;/p&gt;</description>
    </item>
    <item>
      <title>Morepen Laboratories Ltd:Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/morepen-laboratories-ltdannual-report-2023-24-analysis/</link>
      <pubDate>Wed, 04 Sep 2024 15:52:36 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/morepen-laboratories-ltdannual-report-2023-24-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;morepen-laboratories-ltd-a-comprehensive-overview&#34;&gt;&#xA;  Morepen Laboratories Ltd.: A Comprehensive Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#morepen-laboratories-ltd-a-comprehensive-overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;about-the-company&#34;&gt;&#xA;  About the Company&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#about-the-company&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;&lt;strong&gt;Year of Establishment and Founding History:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Morepen Laboratories Ltd. was established in 1984 by Mr. Sushil Suri. It initially started as a marketing company and gradually transitioned into manufacturing.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Headquarters Location and Global Presence:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;The company&amp;rsquo;s headquarters are located in Baddi, Himachal Pradesh, India. Morepen Laboratories has a global presence, exporting its products to various countries across the globe, including North America, Europe, and Asia.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
